Reuters logo
BRIEF-Merck says FDA approves keytruda for treatment of patients with refractory classical hodgkin lymphoma
2017年3月14日 / 晚上9点19分 / 6 个月前

BRIEF-Merck says FDA approves keytruda for treatment of patients with refractory classical hodgkin lymphoma

March 14 (Reuters) - Merck & Co Inc

* FDA approves Merck’s Keytruda® (pembrolizumab) for adult and pediatric patients with classical hodgkin lymphoma (chl) refractory to treatment, or who have relapsed after three or more prior lines of therapy

* Merck & Co - FDA has approved keytruda for treatment of adult and pediatric patients with refractory classical hodgkin lymphoma Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below